Glaukos Corp. - רווח נקי למניה אחת בשנים עשר החודשים האחרונים GKOS

Glaukos Corporation (GKOS) high-precision ophthalmic implant production facilities are operating at maximum capacity to sustain demand for iStent microsurgical solutions and the innovative iDose TR. The annual net income per share TTM trend reflects market expectations, with the -89.00 mark capturing this metric. The integration of microstents with sustained-release drugs is establishing an unrivaled standard for glaucoma therapy, radically transforming medical protocols.
Glaukos Medical - פילוחים אנליטיים ומדדי מפתח (GKOS)

Year-over-year (YoY) EPS growth (TTM) measures the dynamics of net income per share over a rolling twelve-month period, allowing for a continuous assessment of the business's fundamental resilience regardless of quarterly fluctuations. By analyzing the 12-month EPS YoY history, an investor can see how the pricing power of Glaukos Corporation (GKOS) in the MIGS implants segment converts into sustainable profit scaling amid inelastic demand.